

## WHAT IS CLAIMED IS:

1. A method of treating Parkinson's disease in a human in need of such treatment comprising: the administration to a human in need of such treatment of an antiparkinson therapeutic amount of an antiparkinson agent and an anti-inflammatory effective amount of a selective COX-2 inhibitor.

5 2. A method according to claim 1 wherein the antiparkinson agent is selected from an anticholinergic agent; a dopaminergic agent; a monoamine oxidase agent; and amantadine.

10 3. A method according to claim 1 wherein the antiparkinson agent is selected from an anticholinergic agent; a dopaminergic agent; a monoamine oxidase agent; and amantadine.

15 4. A method according to claim 2 wherein the anticholinergic agent comprises an antihistamine agent, an antidepressant, benztropine, biperidene, procyclidine or trihexyphenidyl.

20 5. A method according to claim 2 wherein the anticholinergic agent comprises an anti-histamine agent selected from diphenhydramine and orphenadrine.

25 6. A method according to claim 2 wherein the anticholinergic agent comprises an anti-depressant selected from amitriptyline, doxepin, imipramine and nortriptyline.

7. A method according to claim 2 wherein the dopaminergic agent comprises a dopamine precursor or a dopamine receptor agonist.

30 8. A method according to claim 2 wherein the dopaminergic agent comprises levodopa, bromocriptine, pergolide, pramipexole, cabergoline or ropinirole.

9. A method according to claim 2 wherein the monoamine oxidase agent comprises selegiline.

10. A method according to claim 2 further comprising a second an antiparkinson agent.

5 11. A method for the treating Hoehn & Yahr Stage I-III Parkinson's disease, which method comprises administration to a patient in need of such treatment of an amount of a selective COX-2 inhibitor and an amount of an anti-parkinsonism agent, such that together they provide effective treatment.

10 12. A method of relieving the symptoms of Parkinson's disease, which method comprises administration to a patient in need of such treatment of an amount of a selective COX-2 inhibitor and an amount of an antiparkinson agent, such that together they provide effective relief.

15 13. A method of treating Parkinson's disease, which method comprises administration to a patient in need of such treatment of an amount of a selective COX-2 inhibitor and an amount of an anti-parkinsonism agent, such that together the agents provide greater relief than that obtained by administration of the antiparkinson agent alone.

20 14. A method for ameliorating the progress of Parkinson's disease, which method comprises administration to a patient in need of such treatment of a therapeutically effective amount of a selective COX-2 inhibitor and an amount of an antiparkinson agent, such that together they provide effective amelioration.

25 15. A method for slowing the progress of Parkinson's disease, which method comprises administration to a patient in need of such treatment of a therapeutically effective amount of a selective COX-2 inhibitor and an amount of a antiparkinson agent, such that together they are effective in slowing the progress of the disease.

30 16. A method of treating Parkinson's disease in patients for which symptomatic relief by administration of an antiparkinson agent is not indicated which method comprises administration to a patient in need of such treatment of a therapeutically effective amount of a selective COX-2 inhibitor.

17. A method according to Claim 16 in wherein said patients have early stage Parkinson's disease and patients with minimal or mild symptoms of Parkinson's disease.

5 18. A method of for slowing the progress of Parkinson's disease, which method comprises administration to a patient in need of such treatment of a therapeutically effective amount of a selective COX-2 inhibitor.

10 19. A method of preventing Parkinson's disease comprising administration to a patient in need of such protection of a therapeutically effective amount of a selective COX-2 inhibitor.

20. A method according to Claim 1 to 19, wherein the selective COX-2 inhibitor is VIOXX.